Adenosine

Sold as Adenocard, Adenoscan. Every FDA application for this active ingredient: 2 branded and 23 generic.

As of Nov 13, 2026, FDA lists 25 applications for Adenosine (sold as Adenocard, Adenoscan), first approved Oct 30, 1989, with 1 new use approved and 0 published complete response letters.

First approved: Oct 30, 1989
Applications: 25
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $153K

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Adenocard	Part B	$153K	-42%	6,962

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Oct 30, 1989	AdenocardNDA 19937 · New molecular entity	Astellas	21	Discontinued
May 18, 1995	AdenoscanNDA 20059 · TYPE 6	Astellas	14	Discontinued
Jun 16, 2004	AdenosineANDA 76404	Hikma	1	Marketed
Jun 16, 2004	AdenosineANDA 76500	Hikma	2	Marketed
Jun 16, 2004	AdenosineANDA 76501	Hikma	3	Discontinued
Jun 16, 2004	AdenosineANDA 76564	Teva Pharms USA	1	Discontinued
Apr 27, 2005	AdenosineANDA 77133	Fresenius Kabi USA	2	Marketed
Jun 14, 2007	AdenosineANDA 77283	Gland Pharma Ltd	3	Marketed
Jul 31, 2008	AdenosineANDA 78676	Teva Pharms USA	2	Discontinued
Oct 31, 2008	AdenosineANDA 78076	Rising	2	Marketed
Apr 28, 2009	AdenosineANDA 90010	Am Regent	1	Discontinued
May 13, 2009	AdenosineANDA 78686	Mylan Labs Ltd	3	Marketed
Jul 20, 2009	AdenosineANDA 90220	Wockhardt	2	Discontinued
Aug 29, 2013	AdenosineANDA 77425	Meitheal	3	Marketed
Mar 21, 2014	AdenosineANDA 78640	Pharmobedient	0	Discontinued
Mar 24, 2014	AdenosineANDA 203883	Hospira	1	Discontinued
Mar 28, 2014	AdenosineANDA 90212	Mylan Asi	2	Marketed
Sep 15, 2014	AdenosineANDA 202313	Avet Lifesciences	0	Marketed
Oct 2, 2014	AdenosineANDA 90450	Rising	0	Marketed
Nov 2, 2017	AdenosineANDA 205331	Eugia Pharma	0	Marketed
Nov 27, 2017	AdenosineANDA 77897	Fresenius Kabi USA	0	Marketed
Feb 16, 2018	AdenosineANDA 206778	Gland	0	Marketed
Apr 16, 2018	AdenosineANDA 205568	Fresenius Kabi USA	0	Marketed
—	AdenosineANDA 78618	Bedford Labs	0	Discontinued
—	AdenosineANDA 79147	Wockhardt	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA